AU2013203459A1 - DLL3 modulators and methods of use - Google Patents
DLL3 modulators and methods of useInfo
- Publication number
- AU2013203459A1 AU2013203459A1 AU2013203459A AU2013203459A AU2013203459A1 AU 2013203459 A1 AU2013203459 A1 AU 2013203459A1 AU 2013203459 A AU2013203459 A AU 2013203459A AU 2013203459 A AU2013203459 A AU 2013203459A AU 2013203459 A1 AU2013203459 A1 AU 2013203459A1
- Authority
- AU
- Australia
- Prior art keywords
- methods
- dll3 modulators
- dll3
- modulators
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102100013694 DLL3 Human genes 0.000 title 1
- 101700003144 DLL3 Proteins 0.000 title 1
- 230000000051 modifying Effects 0.000 title 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2016244333A AU2016244333B2 (en) | 2012-02-24 | 2016-10-14 | DLL3 modulators and methods of use |
| AU2018282328A AU2018282328A1 (en) | 2012-02-24 | 2018-12-19 | DLL3 modulators and methods of use |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261603173P | 2012-02-24 | 2012-02-24 | |
| US61/603,173 | 2012-02-24 | ||
| US201261719803P | 2012-10-29 | 2012-10-29 | |
| US61/719,803 | 2012-10-29 | ||
| PCT/US2013/027391 WO2013126746A2 (en) | 2012-02-24 | 2013-02-22 | Novel modulators and methods of use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2016244333A Division AU2016244333B2 (en) | 2012-02-24 | 2016-10-14 | DLL3 modulators and methods of use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2013203459A1 true AU2013203459A1 (en) | 2013-09-12 |
| AU2013203459B2 AU2013203459B2 (en) | 2016-11-03 |
Family
ID=47790544
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2013203459A Ceased AU2013203459B2 (en) | 2012-02-24 | 2013-02-22 | DLL3 modulators and methods of use |
| AU2016244333A Ceased AU2016244333B2 (en) | 2012-02-24 | 2016-10-14 | DLL3 modulators and methods of use |
| AU2018282328A Abandoned AU2018282328A1 (en) | 2012-02-24 | 2018-12-19 | DLL3 modulators and methods of use |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2016244333A Ceased AU2016244333B2 (en) | 2012-02-24 | 2016-10-14 | DLL3 modulators and methods of use |
| AU2018282328A Abandoned AU2018282328A1 (en) | 2012-02-24 | 2018-12-19 | DLL3 modulators and methods of use |
Country Status (30)
| Country | Link |
|---|---|
| US (31) | US9089616B2 (en) |
| EP (4) | EP3093294A1 (en) |
| JP (4) | JP6089047B2 (en) |
| KR (1) | KR20150003169A (en) |
| CN (1) | CN104520324A (en) |
| AU (3) | AU2013203459B2 (en) |
| BR (1) | BR112014020826A8 (en) |
| CA (2) | CA2865404C (en) |
| CL (2) | CL2014002240A1 (en) |
| CO (1) | CO7111274A2 (en) |
| CY (1) | CY1119590T1 (en) |
| DK (1) | DK2817338T3 (en) |
| ES (2) | ES2812849T3 (en) |
| HK (4) | HK1231486A1 (en) |
| HR (1) | HRP20171549T1 (en) |
| HU (1) | HUE037021T2 (en) |
| IL (2) | IL234155B (en) |
| LT (1) | LT2817338T (en) |
| ME (1) | ME02928B (en) |
| MX (2) | MX2014010074A (en) |
| NZ (1) | NZ628804A (en) |
| PE (2) | PE20190658A1 (en) |
| PH (1) | PH12014501876A1 (en) |
| PL (1) | PL2817338T3 (en) |
| PT (1) | PT2817338T (en) |
| RS (1) | RS56443B1 (en) |
| RU (1) | RU2014138474A (en) |
| SG (2) | SG11201405131XA (en) |
| SI (1) | SI2817338T1 (en) |
| WO (1) | WO2013126746A2 (en) |
Families Citing this family (105)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT3342786T (en) * | 2010-01-29 | 2021-10-25 | Chugai Seiyaku Kabushiki Kaisha | Anti-dll3 antibody |
| SG11201405131XA (en) | 2012-02-24 | 2014-10-30 | Stemcentrx Inc | Dll3 modulators and methods of use |
| DK2888283T3 (en) | 2012-08-24 | 2018-11-19 | Univ California | ANTIBODIES AND VACCINES FOR TREATING ROR1 CANCER AND INHIBITIVE METASTASE |
| GB201302447D0 (en) | 2013-02-12 | 2013-03-27 | Oxford Biotherapeutics Ltd | Therapeutic and diagnostic target |
| MX2015010682A (en) * | 2013-02-22 | 2016-05-31 | Stemcentrx Inc | Novel antibody conjugates and uses thereof. |
| BR112016004073A8 (en) * | 2013-08-28 | 2018-06-12 | Stemcentrx Inc | ENGINEERED ANTIBODIES, ANTIBODY DRUG CONJUGATES, THEIR METHOD OF PREPARATION AND THEIR USE, PHARMACEUTICAL COMPOSITION AND THEIR USE, KITS, AND METHODS FOR ADMINISTERING A PYRROLOBENZODIAZEPINE (PBD) TO A CANCER CELL THAT EXPRESSES DLL3 AND FOR DETERMINING THE CYTOTOXICITY OF A ANTI-DLL3 DRUG ANTIBODY CONJUGATE |
| MX2016002547A (en) | 2013-08-28 | 2016-06-17 | Stemcentrx Inc | Site-specific antibody conjugation methods and compositions. |
| MX2016005762A (en) | 2013-11-11 | 2016-08-19 | Chugai Pharmaceutical Co Ltd | Antigen-binding molecule containing modified antibody variable region. |
| TWI700295B (en) | 2013-12-16 | 2020-08-01 | 馬來西亞商Ｍａｂ探索私人有限公司 | Antibodies specific for enteroviruses that infect humans |
| CR20160437A (en) * | 2014-02-21 | 2017-02-20 | Abbvie Stemcentrx Llc | CONJUGATES OF ANTI-DROSOPHILA ANTIBODIES SIMILAR TO DELTA 3 (ANTI-DLL3) AND MEDICINES FOR USE IN THE TREATMENT AGAINST MELANOMA |
| TWI695013B (en) | 2014-04-10 | 2020-06-01 | 台灣浩鼎生技股份有限公司 | Antibodies, hybridoma for producing the antibodies, pharmaceutical compositions comprising the antibodies and uses thereof |
| AU2015294834B2 (en) | 2014-07-31 | 2021-04-29 | Amgen Research (Munich) Gmbh | Optimized cross-species specific bispecific single chain antibody constructs |
| US9732145B2 (en) * | 2014-07-31 | 2017-08-15 | The Israel Institute of Biological Research (IIBR) | Antibodies directed to Bacillus anthracis protective antigen |
| TW202313697A (en) | 2014-11-11 | 2023-04-01 | 日商中外製藥股份有限公司 | Library of antigen-binding molecules including modified antibody variable region |
| MA41613A (en) * | 2015-02-23 | 2018-01-02 | Abbvie Stemcentrx Llc | ANTI-DLL3 CHEMERICAL ANTIGENIC RECEPTORS AND METHODS FOR USING SUCH RECEIVERS |
| JP6688551B2 (en) | 2015-05-21 | 2020-04-28 | ハープーン セラピューティクス，インク． | Trispecific binding proteins and methods of use |
| WO2016207103A1 (en) * | 2015-06-23 | 2016-12-29 | Bayer Pharma Aktiengesellschaft | Antibody drug conjugates of kinesin spindel protein (ksp) inhibitors with anti-b7h3-antibodies |
| WO2017011550A1 (en) * | 2015-07-13 | 2017-01-19 | University Of Utah Research Foundation | Methods of making red blood cells and platelets in vitro and uses thereof |
| TW202346349A (en) * | 2015-07-31 | 2023-12-01 | 德商安美基研究（慕尼黑）公司 | Antibody constructs for dll3 and cd3 |
| TWI829617B (en) | 2015-07-31 | 2024-01-21 | 德商安美基研究（慕尼黑）公司 | Antibody constructs for flt3 and cd3 |
| TWI796283B (en) | 2015-07-31 | 2023-03-21 | 德商安美基研究（慕尼黑）公司 | Antibody constructs for msln and cd3 |
| BR112018003269A2 (en) * | 2015-08-20 | 2018-09-25 | Abbvie Stemcentrx Llc | anti-dll3 drug-antibody conjugates and methods of use |
| WO2017041027A1 (en) | 2015-09-04 | 2017-03-09 | Obi Pharma, Inc. | Glycan arrays and method of use |
| AU2016365114A1 (en) | 2015-11-30 | 2018-05-17 | Abbvie Biotherapeutics Inc. | Anti-huLRRC15 antibody drug conjugates and methods for their use |
| CA3006610A1 (en) | 2015-11-30 | 2017-06-08 | Abbvie Inc. | Anti-hulrrc15 antibody drug conjugates and methods for their use |
| EA039859B1 (en) | 2016-02-03 | 2022-03-21 | Эмджен Рисерч (Мюник) Гмбх | Bispecific antibody constructs binding egfrviii and cd3 |
| EA039325B1 (en) * | 2016-02-03 | 2022-01-13 | Эмджен Рисерч (Мюник) Гмбх | Bispecific antibody constructs binding dll3 and cd3 |
| EP3430072B1 (en) | 2016-03-17 | 2020-07-01 | Merck Patent GmbH | Method for purifying poloxamers |
| US10980894B2 (en) | 2016-03-29 | 2021-04-20 | Obi Pharma, Inc. | Antibodies, pharmaceutical compositions and methods |
| WO2017172990A1 (en) * | 2016-03-29 | 2017-10-05 | Obi Pharma, Inc. | Antibodies, pharmaceutical compositions and methods |
| AU2017246794A1 (en) | 2016-04-04 | 2018-10-25 | Genzyme Corporation | Anti-complement factor Bb antibodies and uses thereof |
| MY200886A (en) | 2016-04-22 | 2024-01-22 | Obi Pharma Inc | Cancer Immunotherapy by Immune Activation or Immune Modulation Via Globo Series Antigens |
| US11623958B2 (en) | 2016-05-20 | 2023-04-11 | Harpoon Therapeutics, Inc. | Single chain variable fragment CD3 binding proteins |
| IL263102B2 (en) | 2016-05-20 | 2023-11-01 | Harpoon Therapeutics Inc | Single domain serum albumin binding protein |
| JP7109007B2 (en) | 2016-06-27 | 2022-07-29 | ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア | Cancer treatment combination |
| AU2017302038B2 (en) | 2016-07-27 | 2024-03-21 | Obi Pharma, Inc. | Immunogenic/therapeutic glycan compositions and uses thereof |
| KR102528998B1 (en) | 2016-07-29 | 2023-05-03 | 오비아이 파머 인코퍼레이티드 | Human Antibodies, Pharmaceutical Compositions and Methods |
| KR20190035863A (en) | 2016-08-05 | 2019-04-03 | 알라코스 인크. | Anti-Siglec-7 Antibody for Cancer Treatment |
| US10042362B2 (en) | 2016-11-18 | 2018-08-07 | Waymo Llc | Dynamic routing for autonomous vehicles |
| TWI767959B (en) | 2016-11-21 | 2022-06-21 | 台灣浩鼎生技股份有限公司 | Conjugated biological molecules, pharmaceutical compositions and methods |
| EP3545000A4 (en) | 2016-11-22 | 2020-07-08 | DendroCyte BioTech Pty Ltd | Anti-cd300f antibody and uses thereof |
| KR20190087539A (en) | 2016-11-23 | 2019-07-24 | 하푼 테라퓨틱스, 인크. | PSMA-targeted triple specific proteins and methods of use |
| BR112019010604A2 (en) | 2016-11-23 | 2019-12-17 | Harpoon Therapeutics Inc | prostate-specific membrane antigen binding protein |
| GB201700553D0 (en) | 2017-01-12 | 2017-03-01 | Genagon Therapeutics Ab | Therapeutic agents |
| US11535668B2 (en) | 2017-02-28 | 2022-12-27 | Harpoon Therapeutics, Inc. | Inducible monovalent antigen binding protein |
| IL300964A (en) | 2017-05-12 | 2023-04-01 | Harpoon Therapeutics Inc | Mesothelin binding proteins |
| KR20200026810A (en) | 2017-05-12 | 2020-03-11 | 하푼 테라퓨틱스, 인크. | MSLN targeting trispecific proteins and methods of use |
| KR20200041897A (en) | 2017-08-01 | 2020-04-22 | 에이비 스튜디오 인코포레이티드 | Bispecific antibodies and uses thereof |
| JP7369121B2 (en) | 2017-10-11 | 2023-10-25 | バイオベラティブ・ユーエスエイ・インコーポレイテッド | How to induce complement activity |
| KR102429747B1 (en) | 2017-10-13 | 2022-08-05 | 하푼 테라퓨틱스, 인크. | B cell maturation antigen binding protein |
| EP3694529A4 (en) | 2017-10-13 | 2021-11-10 | Harpoon Therapeutics, Inc. | Trispecific proteins and methods of use |
| JP7357616B2 (en) | 2017-12-05 | 2023-10-06 | 中外製薬株式会社 | Antigen-binding molecules comprising engineered antibody variable regions that bind to CD3 and CD137 |
| EP3732195A4 (en) | 2017-12-28 | 2022-02-09 | Chugai Seiyaku Kabushiki Kaisha | Cytotoxicity-inducing therapeutic agent |
| AU2019208025A1 (en) * | 2018-01-11 | 2020-09-03 | Allakos, Inc. | Anti-Siglec-7 antibodies having reduced effector function |
| CN112074278B (en) * | 2018-04-03 | 2023-04-25 | 湖南远泰生物技术有限公司 | BCMA-CAR-T cells |
| WO2019195408A1 (en) * | 2018-04-03 | 2019-10-10 | Dragonfly Therapeutics, Inc. | Antibody variable domains targeting dll3, and use thereof |
| MX2020010753A (en) * | 2018-04-10 | 2021-01-29 | Amgen Inc | Chimeric receptors to dll3 and methods of use thereof. |
| JP7455388B2 (en) * | 2018-05-08 | 2024-03-26 | フェインズ セラピューティクス，インコーポレーテッド | Anti-DLL3 antibody and its use |
| TW202016151A (en) | 2018-06-09 | 2020-05-01 | 德商百靈佳殷格翰國際股份有限公司 | Multi-specific binding proteins for cancer treatment |
| WO2020006176A1 (en) | 2018-06-27 | 2020-01-02 | Obi Pharma, Inc. | Glycosynthase variants for glycoprotein engineering and methods of use |
| WO2020028864A1 (en) | 2018-08-02 | 2020-02-06 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| US11911484B2 (en) | 2018-08-02 | 2024-02-27 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| JP2021532831A (en) | 2018-08-02 | 2021-12-02 | ダイン セラピューティクス, インコーポレーテッドDyne Therapeutics, Inc. | Muscle-targeted complexes and their use to treat dystrophin disorders |
| US10815311B2 (en) * | 2018-09-25 | 2020-10-27 | Harpoon Therapeutics, Inc. | DLL3 binding proteins and methods of use |
| US20200102373A1 (en) * | 2018-09-27 | 2020-04-02 | Colorado State University Research Foundation | Scfv's for live cell imaging and other uses |
| KR20210109587A (en) * | 2018-12-27 | 2021-09-06 | 아케소 바이오파마, 인크. | Antibodies to human IL-4RA and uses thereof |
| EP3930744A1 (en) | 2019-03-01 | 2022-01-05 | Allogene Therapeutics, Inc. | Dll3 targeting chimeric antigen receptors and binding agents |
| EP3908679A1 (en) * | 2019-03-08 | 2021-11-17 | OncoLab Diagnostics GmbH | Cancer diagnosis and prognosis |
| WO2020210067A1 (en) * | 2019-04-08 | 2020-10-15 | Phanes Therapeutics, Inc. | Humanized anti-dll3 chimeric antigen receptors and uses thereof |
| JP2022530089A (en) * | 2019-04-24 | 2022-06-27 | マジェンタ セラピューティクス インコーポレイテッド | Anti-CD45 antibody drug conjugate and its usage |
| CN114341182A (en) * | 2019-07-11 | 2022-04-12 | 纪念斯隆凯特琳癌症中心 | DLL3 targeting antibodies and uses thereof |
| WO2021041300A2 (en) * | 2019-08-23 | 2021-03-04 | Ab Therapeutics, Inc. | Bispecific antibodies and uses thereof |
| CN112442126B (en) * | 2019-09-04 | 2022-07-29 | 杭州济元基因科技有限公司 | Monoclonal antibody of anti-human CS1 antigen and CAR-T cell thereof |
| EP3819312A1 (en) * | 2019-11-10 | 2021-05-12 | Amgen, Inc | Dosing regimen for anti-dll3 agents |
| US20230226212A1 (en) * | 2020-01-10 | 2023-07-20 | Dyne Therapeutics, Inc. | Muscle-targeting complexes and uses thereof |
| AU2021205346A1 (en) * | 2020-01-10 | 2022-09-01 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| BR112022013603A2 (en) * | 2020-01-10 | 2022-09-13 | Dyne Therapeutics Inc | MUSCLE TARGETING COMPLEXES AND USES THEM TO TREAT FACIOSCAPULOUMERAL MUSCULAR DYSTROPHY |
| CA3164090A1 (en) | 2020-01-10 | 2021-07-15 | Jonathan Kurtis | Antibodies to pfgarp kill plasmodium falciparum malaria parasites and protect against infection and severe disease |
| CA3163295A1 (en) * | 2020-01-10 | 2021-07-15 | Romesh R. Subramanian | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US20230117883A1 (en) * | 2020-01-24 | 2023-04-20 | Dyne Therapeutics, Inc. | Muscle-targeting complexes and uses thereof in treating muscle atrophy |
| EP4106819A1 (en) | 2020-02-21 | 2022-12-28 | Silverback Therapeutics, Inc. | Nectin-4 antibody conjugates and uses thereof |
| CN115768463A (en) | 2020-02-21 | 2023-03-07 | 哈普恩治疗公司 | FLT 3-binding proteins and methods of use |
| US20210269551A1 (en) * | 2020-02-25 | 2021-09-02 | Gensun Biopharma Inc. | Trispecific T cell Engagers |
| EP4126969A4 (en) | 2020-03-31 | 2024-05-29 | Chugai Pharmaceutical Co Ltd | Dll3-targeting multispecific antigen-binding molecules and uses thereof |
| IL296802A (en) | 2020-03-31 | 2022-11-01 | Chugai Pharmaceutical Co Ltd | Method for producing multispecific antigen-binding molecules |
| CA3173325A1 (en) | 2020-04-20 | 2021-10-28 | Graham Parry | Humanized anti-complement factor bb antibodies and uses thereof |
| WO2021216832A1 (en) * | 2020-04-23 | 2021-10-28 | Remd Biotherapeutics, Inc. | Chemokine receptor 4 (cxcr4) antagonist antibodies |
| CA3183993A1 (en) | 2020-07-01 | 2022-01-06 | Peter R. Baum | Anti-asgr1 antibody conjugates and uses thereof |
| CA3194771A1 (en) | 2020-09-16 | 2022-03-24 | Amgen Inc. | Methods for administering therapeutic doses of bispecific t-cell engaging molecules for the treatment of cancer |
| WO2022087316A1 (en) * | 2020-10-21 | 2022-04-28 | La Jolla Institute For Immunology | Chimeric anti-sars-cov2 nucleoprotein antibodies |
| TW202241935A (en) | 2020-12-18 | 2022-11-01 | 美商世紀治療股份有限公司 | Chimeric antigen receptor system with adaptable receptor specificity |
| TW202237135A (en) | 2021-01-13 | 2022-10-01 | 紀念斯隆凱特琳癌症中心 | Antibody-pyrrolobenzodiazepine derivative conjugate |
| TW202245844A (en) | 2021-01-13 | 2022-12-01 | 紀念斯隆凱特琳癌症中心 | Anti-dll3 antibody-drug conjugate |
| US11633498B2 (en) | 2021-07-09 | 2023-04-25 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US11638761B2 (en) | 2021-07-09 | 2023-05-02 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy |
| US11969475B2 (en) | 2021-07-09 | 2024-04-30 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| US11771776B2 (en) | 2021-07-09 | 2023-10-03 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| CN113528583A (en) * | 2021-07-15 | 2021-10-22 | 澳门大学 | Automatic microinjection method, device, system, equipment and storage medium |
| WO2023006084A1 (en) | 2021-07-30 | 2023-02-02 | 上海复旦张江生物医药股份有限公司 | Anti-dll3 antibody and preparation method therefor, drug conjugate and application thereof |
| WO2023023354A2 (en) * | 2021-08-19 | 2023-02-23 | Adicet Therapeutics, Inc. | Methods for detection of membrane bound glypican-3 |
| WO2023053272A1 (en) | 2021-09-29 | 2023-04-06 | Chugai Seiyaku Kabushiki Kaisha | Uses of dll3-targeting multispecific antigen-binding molecules |
| US11931421B2 (en) | 2022-04-15 | 2024-03-19 | Dyne Therapeutics, Inc. | Muscle targeting complexes and formulations for treating myotonic dystrophy |
| WO2023225197A2 (en) * | 2022-05-18 | 2023-11-23 | The Brigham And Women’S Hospital, Inc. | Klrb1 binding agents and methods of use thereof |
| CN116355079B (en) * | 2022-08-19 | 2023-12-26 | 上海迈科康生物科技有限公司 | Monoclonal antibody for detecting recombinant human rotavirus VP8 antigen (VP 8P 8) and application thereof |
| CN116966202B (en) * | 2023-09-22 | 2023-12-01 | 再少年(北京)生物科技有限公司 | Application of iPS induced directional differentiation neural stem cell combined drug in treating Alzheimer's disease |
Family Cites Families (146)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR901464A (en) | 1943-01-23 | 1945-07-27 | Boehringer & Soehne Gmbh | Process for obtaining vanillin |
| FR2413974A1 (en) | 1978-01-06 | 1979-08-03 | David Bernard | DRYER FOR SCREEN-PRINTED SHEETS |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4703004A (en) | 1984-01-24 | 1987-10-27 | Immunex Corporation | Synthesis of protein with an identification peptide |
| EP0216846B2 (en) | 1985-04-01 | 1995-04-26 | Celltech Limited | Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| JP3101690B2 (en) | 1987-03-18 | 2000-10-23 | エス・ビィ・２・インコーポレイテッド | Modifications of or for denatured antibodies |
| US5750172A (en) | 1987-06-23 | 1998-05-12 | Pharming B.V. | Transgenic non human mammal milk |
| GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
| US5336603A (en) | 1987-10-02 | 1994-08-09 | Genentech, Inc. | CD4 adheson variants |
| IL106992A (en) | 1988-02-11 | 1994-06-24 | Bristol Myers Squibb Co | Acylhydrazone derivatives of anthracycline and methods for their preparation |
| US5879936A (en) | 1988-04-18 | 1999-03-09 | Aluguisse Holding A.G. | Recombinant DNA methods, vectors and host cells |
| GB8809129D0 (en) | 1988-04-18 | 1988-05-18 | Celltech Ltd | Recombinant dna methods vectors and host cells |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| KR900005995A (en) | 1988-10-31 | 1990-05-07 | 우메모또 요시마사 | Modified Interleukin-2 and Method of Making the Same |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| ATE144793T1 (en) | 1989-06-29 | 1996-11-15 | Medarex Inc | BISPECIFIC REAGENTS FOR AIDS THERAPY |
| US5112946A (en) | 1989-07-06 | 1992-05-12 | Repligen Corporation | Modified pf4 compositions and methods of use |
| FR2650598B1 (en) | 1989-08-03 | 1994-06-03 | Rhone Poulenc Sante | DERIVATIVES OF ALBUMIN WITH THERAPEUTIC FUNCTION |
| WO1991006570A1 (en) | 1989-10-25 | 1991-05-16 | The University Of Melbourne | HYBRID Fc RECEPTOR MOLECULES |
| US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
| US5633076A (en) | 1989-12-01 | 1997-05-27 | Pharming Bv | Method of producing a transgenic bovine or transgenic bovine embryo |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5314995A (en) | 1990-01-22 | 1994-05-24 | Oncogen | Therapeutic interleukin-2-antibody based fusion proteins |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| US5349053A (en) | 1990-06-01 | 1994-09-20 | Protein Design Labs, Inc. | Chimeric ligand/immunoglobulin molecules and their uses |
| KR0149181B1 (en) | 1990-06-29 | 1998-08-17 | 데이비드 알, 맥지 | Melanin production by transformed microorganisms |
| ES2139598T3 (en) | 1990-07-10 | 2000-02-16 | Medical Res Council | PROCEDURES FOR THE PRODUCTION OF SPECIFIC UNION COUPLE MEMBERS. |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| CA2089661C (en) | 1990-08-29 | 2007-04-03 | Nils Lonberg | Transgenic non-human animals capable of producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| DK0564531T3 (en) | 1990-12-03 | 1998-09-28 | Genentech Inc | Enrichment procedure for variant proteins with altered binding properties |
| WO1992010591A1 (en) | 1990-12-14 | 1992-06-25 | Cell Genesys, Inc. | Chimeric chains for receptor-associated signal transduction pathways |
| EP1820858B1 (en) | 1991-03-01 | 2009-08-12 | Dyax Corporation | Chimeric protein comprising micro-protein having two or more disulfide bonds and embodiments thereof |
| CA2108147C (en) | 1991-04-10 | 2009-01-06 | Angray Kang | Heterodimeric receptor libraries using phagemids |
| EP0586505A1 (en) | 1991-05-14 | 1994-03-16 | Repligen Corporation | Heteroconjugate antibodies for treatment of hiv infection |
| DE4122599C2 (en) | 1991-07-08 | 1993-11-11 | Deutsches Krebsforsch | Phagemid for screening antibodies |
| US5622929A (en) | 1992-01-23 | 1997-04-22 | Bristol-Myers Squibb Company | Thioether conjugates |
| US5667988A (en) | 1992-01-27 | 1997-09-16 | The Scripps Research Institute | Methods for producing antibody libraries using universal or randomized immunoglobulin light chains |
| FR2686901A1 (en) | 1992-01-31 | 1993-08-06 | Rhone Poulenc Rorer Sa | NOVEL ANTITHROMBOTIC POLYPEPTIDES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. |
| FR2686899B1 (en) | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | NOVEL BIOLOGICALLY ACTIVE POLYPEPTIDES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. |
| US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
| US5447851B1 (en) | 1992-04-02 | 1999-07-06 | Univ Texas System Board Of | Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells |
| ZA932522B (en) | 1992-04-10 | 1993-12-20 | Res Dev Foundation | Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens |
| CA2140280A1 (en) | 1992-08-17 | 1994-03-03 | Avi J. Ashkenazi | Bispecific immunoadhesins |
| WO1994004670A1 (en) | 1992-08-26 | 1994-03-03 | President And Fellows Of Harvard College | Use of the cytokine ip-10 as an anti-tumor agent |
| US7744877B2 (en) | 1992-11-13 | 2010-06-29 | Biogen Idec Inc. | Expression and use of anti-CD20 Antibodies |
| JP3095175B2 (en) | 1992-11-13 | 2000-10-03 | アイデック ファーマシューティカルズ コーポレイション | Therapeutic use of chimeric and radiolabeled antibodies against human B lymphocyte restricted differentiation antigen for the treatment of B cell lymphoma |
| ATE193301T1 (en) | 1993-03-09 | 2000-06-15 | Genzyme Corp | METHOD FOR ISOLATION OF PROTEINS FROM MILK |
| US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
| US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
| SK282439B6 (en) | 1994-07-13 | 2002-02-05 | Sca Hygiene Paper Ab | Production method of nonwoven material |
| CN1117155C (en) | 1994-07-29 | 2003-08-06 | 史密丝克莱恩比彻姆有限公司 | Novel compounds |
| US6046037A (en) | 1994-12-30 | 2000-04-04 | Hiatt; Andrew C. | Method for producing immunoglobulins containing protection proteins in plants and their use |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| CA2229043C (en) | 1995-08-18 | 2016-06-07 | Morphosys Gesellschaft Fur Proteinoptimierung Mbh | Protein/(poly)peptide libraries |
| PT871490E (en) | 1995-12-22 | 2003-07-31 | Bristol Myers Squibb Co | BRIDGED HIDRAZONE LIGANTS |
| WO1997033899A1 (en) | 1996-03-14 | 1997-09-18 | Human Genome Sciences, Inc. | Apoptosis inducing molecule i |
| DE69731289D1 (en) | 1996-03-18 | 2004-11-25 | Univ Texas | IMMUNGLOBULIN-LIKE DOMAIN WITH INCREASED HALF-VALUE TIMES |
| CA2248868A1 (en) | 1996-03-22 | 1997-09-25 | Human Genome Sciences, Inc. | Apoptosis inducing molecule ii |
| US20030180784A1 (en) * | 1997-04-04 | 2003-09-25 | Millennium Pharmaceuticals, Inc. | Novel human Delta3 compositions and therapeutic and diagnostic uses therefor |
| WO1998052976A1 (en) | 1997-05-21 | 1998-11-26 | Biovation Limited | Method for the production of non-immunogenic proteins |
| JP4441112B2 (en) | 1997-11-03 | 2010-03-31 | ヒューマン ジノーム サイエンシーズ， インコーポレイテッド | VEGI is an inhibitor of angiogenesis and tumor growth |
| WO1999029888A1 (en) | 1997-12-05 | 1999-06-17 | The Scripps Research Institute | Humanization of murine antibody |
| ES2244210T3 (en) | 1998-08-27 | 2005-12-01 | Spirogen Limited | PIRROLOBENZODIAZEPINAS. |
| GB9818731D0 (en) | 1998-08-27 | 1998-10-21 | Univ Portsmouth | Compounds |
| CN1202128C (en) | 1998-12-08 | 2005-05-18 | 拜奥威神有限公司 | Method for reducing immunogenicity of proteins |
| PL209786B1 (en) | 1999-01-15 | 2011-10-31 | Genentech Inc | Variant of mother polypeptide containing Fc region, polypeptide containing variant of Fc region with altered affinity of Fc gamma receptor binding (Fc R), polypeptide containing variant of Fc region with altered affinity of Fc gamma neonatal receptor binding (Fc Rn), composition, isolated nucleic acid, vector, host cell, method for obtaining polypeptide variant, the use thereof and method for obtaining region Fc variant |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US6908748B2 (en) | 1999-07-29 | 2005-06-21 | Kenji Sobue | Genes associated with the maintenance of differentiation of smooth muscle cells |
| US6703221B1 (en) | 1999-08-19 | 2004-03-09 | Chiron Corporation | Notch receptor ligands and uses thereof |
| AU6913100A (en) | 1999-08-19 | 2001-03-13 | Chiron Corporation | Notch receptor ligands and uses thereof |
| CA2405563A1 (en) | 2000-04-12 | 2001-10-25 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| AU2001280471A1 (en) | 2000-08-11 | 2002-02-25 | Eli Lilly And Company | Novel secreted proteins and their uses |
| US7138496B2 (en) | 2002-02-08 | 2006-11-21 | Genetastix Corporation | Human monoclonal antibodies against human CXCR4 |
| EP2357187A1 (en) | 2000-12-12 | 2011-08-17 | MedImmune, LLC | Molecules with extended half-lives, compositions and uses thereof |
| US6362331B1 (en) | 2001-03-30 | 2002-03-26 | Council Of Scientific And Industrial Research | Process for the preparation of antitumor agents |
| DE10131904A1 (en) | 2001-07-04 | 2003-01-16 | Putzmeister Ag | Device for conveying flowable or pourable material |
| CA2467633C (en) | 2001-12-03 | 2012-03-27 | Abgenix, Inc. | Antibody categorization based on binding characteristics |
| EP1487492A4 (en) | 2002-03-04 | 2008-10-01 | Medimmune Inc | The prevention or treatment of cancer using integrin alphavbeta3 antagonists in combination with other agents |
| BRPI0314814C1 (en) | 2002-09-27 | 2021-07-27 | Xencor Inc | antibody comprising an fc variant |
| US20040101920A1 (en) | 2002-11-01 | 2004-05-27 | Czeslaw Radziejewski | Modification assisted profiling (MAP) methodology |
| GB0226593D0 (en) | 2002-11-14 | 2002-12-24 | Consultants Ltd | Compounds |
| WO2004072266A2 (en) | 2003-02-13 | 2004-08-26 | Kalobios Inc. | Antibody affinity engineering by serial epitope-guided complementarity replacement |
| ATE516047T1 (en) | 2003-05-09 | 2011-07-15 | Diadexus Inc | OVR110 ANTIBODY COMPOSITIONS AND METHODS OF USE |
| US8029984B2 (en) | 2003-08-08 | 2011-10-04 | Licentia, Ltd. | Materials and methods for colorectal cancer screening, diagnosis and therapy |
| GB0321295D0 (en) | 2003-09-11 | 2003-10-15 | Spirogen Ltd | Synthesis of protected pyrrolobenzodiazepines |
| EP3120861B1 (en) | 2003-11-06 | 2018-08-15 | Seattle Genetics, Inc. | Intermediate for conjugate preparation comprising auristatin derivatives and a linker |
| AU2005216251B2 (en) | 2004-02-23 | 2011-03-10 | Genentech, Inc. | Heterocyclic self-immolative linkers and conjugates |
| WO2005085251A1 (en) | 2004-03-01 | 2005-09-15 | Spirogen Limited | 11-hydroxy-5h-pyrrolo[2,1-c][1,4]benzodiazepin-5-one derivatives as key intermediates for the preparation of c2 substituted pyrrolobenzodiazepines |
| GB0404577D0 (en) | 2004-03-01 | 2004-04-07 | Spirogen Ltd | Pyrrolobenzodiazepines |
| US7189710B2 (en) | 2004-03-30 | 2007-03-13 | Council Of Scientific And Industrial Research | C2-fluoro pyrrolo [2,1−c][1,4]benzodiazepine dimers |
| FR2869231B1 (en) | 2004-04-27 | 2008-03-14 | Sod Conseils Rech Applic | THERAPEUTIC COMPOSITION CONTAINING AT LEAST ONE PYRROLOBENZODIAZEPINE DERIVATIVE AND FLUDARABINE |
| JP4840939B2 (en) | 2004-08-04 | 2011-12-21 | アムジェン インコーポレイテッド | Antibody to DKK-1 |
| CA2580141C (en) | 2004-09-23 | 2013-12-10 | Genentech, Inc. | Cysteine engineered antibodies and conjugates |
| US20070123448A1 (en) | 2005-11-23 | 2007-05-31 | The Hospital For Sick Children | Novel chemical entities affecting neuroblastoma tumor-initiating cells |
| MX2008007650A (en) | 2005-12-16 | 2008-10-20 | Genentech Inc | Method for diagnosing, prognosing and treating glioma. |
| US20100184021A1 (en) | 2006-01-16 | 2010-07-22 | Compugen Ltd. | Novel nucleotide and amino acid sequences, and methods of use thereof for diagnosis |
| ES2374964T3 (en) | 2006-01-25 | 2012-02-23 | Sanofi | CYTOTOXIC AGENTS UNDERSTANDING NEW TOMAIMYCIN DERIVATIVES. |
| US8133857B2 (en) | 2006-03-07 | 2012-03-13 | The Brigham and Women's FHospital, Inc. | NOTCH inhibition in the treatment of atherosclerosis |
| CA2658003A1 (en) | 2006-06-06 | 2007-12-21 | University Of Tennessee Research Foundation | Compositions enriched in neoplastic stem cells and methods comprising same |
| EP3520806B1 (en) | 2006-09-07 | 2024-03-20 | Scott & White Memorial Hospital | Methods and compositions based on diphtheria toxin-interleukin-3 conjugates |
| US7825267B2 (en) | 2006-09-08 | 2010-11-02 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Synthesis of FR901464 and analogs with antitumor activity |
| US20100061933A1 (en) | 2006-10-20 | 2010-03-11 | Naoki Kimura | Pharmaceutical composition comprising anti-hb-egf antibody as active ingredient |
| AU2008207945A1 (en) | 2007-01-22 | 2008-07-31 | Macrogenics West, Inc. | Human cancer stem cells |
| US9289492B2 (en) | 2007-07-17 | 2016-03-22 | The General Hospital Corporation | Collecting ovarian cancer stem cells from ovarian cancer cells |
| EP2022848A1 (en) | 2007-08-10 | 2009-02-11 | Hubrecht Institut | A method for identifying, expanding, and removing adult stem cells and cancer stem cells |
| US20090130105A1 (en) | 2007-08-28 | 2009-05-21 | Biogen Idec Ma Inc. | Compositions that bind multiple epitopes of igf-1r |
| WO2009043051A2 (en) | 2007-09-27 | 2009-04-02 | Biogen Idec Ma Inc. | Cd23 binding molecules and methods of use thereof |
| JP2011516520A (en) * | 2008-04-07 | 2011-05-26 | アブリンクス エン．ヴェー． | Amino acid sequence having directivity in Notch pathway and use thereof |
| US8384551B2 (en) | 2008-05-28 | 2013-02-26 | MedHab, LLC | Sensor device and method for monitoring physical stresses placed on a user |
| WO2010037134A2 (en) | 2008-09-29 | 2010-04-01 | Stemlifeline, Inc. | Multi-stage stem cell carcinogenesis |
| US8788213B2 (en) | 2009-01-12 | 2014-07-22 | Intrexon Corporation | Laser mediated sectioning and transfer of cell colonies |
| US20110020221A1 (en) | 2009-04-09 | 2011-01-27 | The Johns Hopkins University | Cancer stem cell expression patterns and compounds to target cancer stem cells |
| LT3342786T (en) * | 2010-01-29 | 2021-10-25 | Chugai Seiyaku Kabushiki Kaisha | Anti-dll3 antibody |
| AU2011239522B2 (en) | 2010-04-15 | 2014-10-23 | Medimmune Limited | Targeted pyrrolobenzodiazapine conjugates |
| JP5875083B2 (en) | 2010-04-15 | 2016-03-02 | メディミューン リミテッド | Pyrrolobenzodiazepine for the treatment of proliferative diseases |
| BR112012026213B1 (en) * | 2010-04-15 | 2021-12-28 | Medimmune Limited | PYRROLOBENZODIAZEPINE COMPOUNDS, CONJUGATE THEREOF, PHARMACEUTICAL COMPOSITION INCLUDING CONJUGATE AND USE THEREOF FOR TREATMENT OF A PROLIFERATIVE DISEASE |
| GB201006340D0 (en) | 2010-04-15 | 2010-06-02 | Spirogen Ltd | Synthesis method and intermediates |
| US20130061342A1 (en) | 2011-09-02 | 2013-03-07 | Stem Centrx, Inc. | Identification and Enrichment of Cell Subpopulations |
| WO2013119964A2 (en) | 2012-02-08 | 2013-08-15 | Stem Centrx, Inc. | Identification and enrichment of cell subpopulations |
| US20130061340A1 (en) | 2011-09-02 | 2013-03-07 | Stem Centrx, Inc. | Identification and Enrichment of Cell Subpopulations |
| US9778264B2 (en) | 2010-09-03 | 2017-10-03 | Abbvie Stemcentrx Llc | Identification and enrichment of cell subpopulations |
| CA2809864A1 (en) | 2010-09-03 | 2012-03-08 | Stem Centrx, Inc. | Identification and enrichment of cell subpopulations |
| KR20240013851A (en) | 2010-09-29 | 2024-01-30 | 어젠시스 인코포레이티드 | Antibody drug conjugates (adc) that bind to 191p4d12 proteins |
| LT2649086T (en) | 2010-12-09 | 2017-11-10 | The Trustees Of The University Of Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| DK2681244T3 (en) | 2011-03-02 | 2018-01-29 | Roche Glycart Ag | CEA ANTIBODIES |
| MX341524B (en) | 2011-09-20 | 2016-08-24 | Medimmune Ltd | Pyrrolobenzodiazepines as unsymmetrical dimeric pbd compounds for inclusion in targeted conjugates. |
| TWI679212B (en) | 2011-11-15 | 2019-12-11 | 美商安進股份有限公司 | Binding molecules for e3 of bcma and cd3 |
| KR20200110476A (en) | 2011-11-16 | 2020-09-23 | 베링거 인겔하임 인터내셔날 게엠베하 | Anti il-36r antibodies |
| SG11201405131XA (en) | 2012-02-24 | 2014-10-30 | Stemcentrx Inc | Dll3 modulators and methods of use |
| GB201302447D0 (en) | 2013-02-12 | 2013-03-27 | Oxford Biotherapeutics Ltd | Therapeutic and diagnostic target |
| MX2015010682A (en) | 2013-02-22 | 2016-05-31 | Stemcentrx Inc | Novel antibody conjugates and uses thereof. |
| US9683039B2 (en) | 2013-03-14 | 2017-06-20 | New York University | Notch agonists for the treatment of cancer |
| BR112016004073A8 (en) | 2013-08-28 | 2018-06-12 | Stemcentrx Inc | ENGINEERED ANTIBODIES, ANTIBODY DRUG CONJUGATES, THEIR METHOD OF PREPARATION AND THEIR USE, PHARMACEUTICAL COMPOSITION AND THEIR USE, KITS, AND METHODS FOR ADMINISTERING A PYRROLOBENZODIAZEPINE (PBD) TO A CANCER CELL THAT EXPRESSES DLL3 AND FOR DETERMINING THE CYTOTOXICITY OF A ANTI-DLL3 DRUG ANTIBODY CONJUGATE |
| MX2016002547A (en) | 2013-08-28 | 2016-06-17 | Stemcentrx Inc | Site-specific antibody conjugation methods and compositions. |
| CR20160437A (en) | 2014-02-21 | 2017-02-20 | Abbvie Stemcentrx Llc | CONJUGATES OF ANTI-DROSOPHILA ANTIBODIES SIMILAR TO DELTA 3 (ANTI-DLL3) AND MEDICINES FOR USE IN THE TREATMENT AGAINST MELANOMA |
| EP3209334A2 (en) | 2014-10-20 | 2017-08-30 | Igenica Biotherapeutics, Inc. | Novel antibody-drug conjugates and related compounds, compositions, and methods of use |
| WO2018026742A1 (en) | 2016-08-01 | 2018-02-08 | Askgene Pharma Inc. | Novel antibody-albumin-drug conjugates (aadc) and methods for using them |
-
2013
- 2013-02-22 SG SG11201405131XA patent/SG11201405131XA/en unknown
- 2013-02-22 ME MEP-2017-185A patent/ME02928B/en unknown
- 2013-02-22 EP EP16164551.0A patent/EP3093294A1/en not_active Withdrawn
- 2013-02-22 ES ES16164567T patent/ES2812849T3/en active Active
- 2013-02-22 WO PCT/US2013/027391 patent/WO2013126746A2/en active Application Filing
- 2013-02-22 PT PT137075255T patent/PT2817338T/en unknown
- 2013-02-22 EP EP16164567.6A patent/EP3095797B1/en active Active
- 2013-02-22 CA CA2865404A patent/CA2865404C/en active Active
- 2013-02-22 EP EP13707525.5A patent/EP2817338B1/en active Active
- 2013-02-22 CN CN201380010475.2A patent/CN104520324A/en active Pending
- 2013-02-22 DK DK13707525.5T patent/DK2817338T3/en active
- 2013-02-22 PE PE2019000670A patent/PE20190658A1/en unknown
- 2013-02-22 SG SG10201806867VA patent/SG10201806867VA/en unknown
- 2013-02-22 RS RS20171006A patent/RS56443B1/en unknown
- 2013-02-22 BR BR112014020826A patent/BR112014020826A8/en not_active Application Discontinuation
- 2013-02-22 PE PE2014001295A patent/PE20150090A1/en active IP Right Grant
- 2013-02-22 AU AU2013203459A patent/AU2013203459B2/en not_active Ceased
- 2013-02-22 HU HUE13707525A patent/HUE037021T2/en unknown
- 2013-02-22 KR KR1020147026844A patent/KR20150003169A/en not_active Application Discontinuation
- 2013-02-22 EP EP16164549.4A patent/EP3093293A1/en not_active Withdrawn
- 2013-02-22 MX MX2014010074A patent/MX2014010074A/en unknown
- 2013-02-22 RU RU2014138474A patent/RU2014138474A/en not_active Application Discontinuation
- 2013-02-22 JP JP2014558882A patent/JP6089047B2/en not_active Expired - Fee Related
- 2013-02-22 LT LTEP13707525.5T patent/LT2817338T/en unknown
- 2013-02-22 SI SI201330800T patent/SI2817338T1/en unknown
- 2013-02-22 NZ NZ628804A patent/NZ628804A/en not_active IP Right Cessation
- 2013-02-22 CA CA3050672A patent/CA3050672A1/en not_active Abandoned
- 2013-02-22 PL PL13707525T patent/PL2817338T3/en unknown
- 2013-02-22 ES ES13707525.5T patent/ES2645272T3/en active Active
-
2014
- 2014-08-17 IL IL234155A patent/IL234155B/en active IP Right Grant
- 2014-08-20 PH PH12014501876A patent/PH12014501876A1/en unknown
- 2014-08-21 MX MX2018010548A patent/MX2018010548A/en unknown
- 2014-08-22 US US14/466,945 patent/US9089616B2/en not_active Expired - Fee Related
- 2014-08-22 US US14/466,948 patent/US9090683B2/en not_active Expired - Fee Related
- 2014-08-22 US US14/466,951 patent/US9089617B2/en not_active Expired - Fee Related
- 2014-08-22 US US14/466,941 patent/US9107961B2/en not_active Expired - Fee Related
- 2014-08-22 CL CL2014002240A patent/CL2014002240A1/en unknown
- 2014-08-22 CO CO14184798A patent/CO7111274A2/en unknown
- 2014-08-22 US US14/466,939 patent/US8986972B2/en active Active
- 2014-08-22 US US14/466,842 patent/US9089615B2/en not_active Expired - Fee Related
-
2015
- 2015-01-19 HK HK17104910.0A patent/HK1231486A1/en unknown
- 2015-01-19 HK HK17104908.4A patent/HK1231485A1/en unknown
- 2015-01-19 HK HK17104918.2A patent/HK1231488A1/en unknown
- 2015-01-19 HK HK15100598.9A patent/HK1200174A1/en not_active IP Right Cessation
- 2015-06-08 US US14/733,874 patent/US9155803B1/en not_active Expired - Fee Related
- 2015-06-17 US US14/742,576 patent/US9133271B1/en not_active Expired - Fee Related
- 2015-07-23 US US14/807,789 patent/US9173959B1/en active Active
- 2015-09-18 US US14/859,242 patent/US9353182B2/en active Active
-
2016
- 2016-01-11 US US14/992,714 patent/US9334318B1/en active Active
- 2016-01-25 US US15/005,918 patent/US9345784B1/en active Active
- 2016-01-25 US US15/005,962 patent/US9352051B1/en active Active
- 2016-01-25 US US15/005,993 patent/US9358304B1/en active Active
- 2016-02-19 JP JP2016030270A patent/JP2016098233A/en active Pending
- 2016-02-19 JP JP2016030269A patent/JP6010241B2/en active Active
- 2016-04-21 US US15/135,517 patent/US9486537B2/en active Active
- 2016-04-21 US US15/135,542 patent/US9480757B2/en active Active
- 2016-04-21 US US15/135,546 patent/US9481727B2/en active Active
- 2016-06-22 CL CL2016001616A patent/CL2016001616A1/en unknown
- 2016-09-15 US US15/266,894 patent/US10137204B2/en active Active
- 2016-10-14 AU AU2016244333A patent/AU2016244333B2/en not_active Ceased
-
2017
- 2017-05-30 US US15/608,988 patent/US9770518B1/en active Active
- 2017-05-30 US US15/608,995 patent/US9764042B1/en active Active
- 2017-05-30 US US15/608,996 patent/US9775916B1/en active Active
- 2017-05-30 US US15/608,991 patent/US9878053B2/en active Active
- 2017-06-07 US US15/616,800 patent/US9855343B2/en active Active
- 2017-06-07 US US15/616,192 patent/US9861708B2/en active Active
- 2017-09-01 US US15/694,602 patent/US9931420B2/en not_active Expired - Fee Related
- 2017-09-01 US US15/694,629 patent/US9937268B2/en not_active Expired - Fee Related
- 2017-09-01 US US15/694,622 patent/US9867887B1/en active Active
- 2017-09-01 US US15/694,627 patent/US9931421B2/en not_active Expired - Fee Related
- 2017-10-12 HR HRP20171549TT patent/HRP20171549T1/en unknown
- 2017-10-20 CY CY20171101098T patent/CY1119590T1/en unknown
-
2018
- 2018-05-29 JP JP2018102094A patent/JP2018162257A/en active Pending
- 2018-10-03 IL IL262110A patent/IL262110A/en unknown
- 2018-10-25 US US16/170,848 patent/US20190046656A1/en not_active Abandoned
- 2018-12-19 AU AU2018282328A patent/AU2018282328A1/en not_active Abandoned
-
2019
- 2019-04-12 US US16/382,868 patent/US20190247510A1/en not_active Abandoned
- 2019-12-06 US US16/706,174 patent/US11033634B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL262110A (en) | Dll3 modulators and methods of use | |
| AU2013203459A1 (en) | DLL3 modulators and methods of use | |
| IL263020A (en) | Novel modulators and methods of use | |
| IL247595A0 (en) | Novel modulators and methods of use | |
| HK1248596A1 (en) | Novel sez6 modulators and methods of use | |
| HK1208439A1 (en) | 5-azaindazole compounds and methods of use 5- | |
| EP2912178A4 (en) | Super-enhancers and methods of use thereof | |
| SG10201601792UA (en) | Novel modulators and methods of use | |
| HRP20181704T1 (en) | Crystal form of chidamide, preparation method and use thereof | |
| EP2852397A4 (en) | Huwentoxin-iv variants and methods of use | |
| EP2895474A4 (en) | Smoothened modulators and methods of use thereof | |
| ZA201408128B (en) | Etract of greyia radlkoferi and use thereof | |
| AU2012900651A0 (en) | Compounds and methods of their use | |
| AU2012900650A0 (en) | Compounds and methods of their use | |
| AU2012903090A0 (en) | Compounds and methods of their use - IV | |
| AU2012901658A0 (en) | Compositions and methods of use | |
| AU2012905377A0 (en) | Bioreactor and method of use | |
| AU2012904991A0 (en) | Therapeutic Compounds and Uses Thereof | |
| AU2012901799A0 (en) | Thermo-Electrochemical Cell and Method of Use |